SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001140361-23-035323
Filing Date
2023-07-20
Accepted
2023-07-20 08:57:11
Documents
17

Document Format Files

Seq Description Document Type Size
1 FORM DEFM14A ny20006478x10_defm14a.htm DEFM14A 10590148
2 ny20006478x10_bargraph01.jpg GRAPHIC 169174
3 ny20006478x10_bargraph02.jpg GRAPHIC 163569
4 ny20006478x10_graphic01.jpg GRAPHIC 279182
5 ny20006478x10_graphic01x1.jpg GRAPHIC 308469
6 ny20006478x10_graphic02.jpg GRAPHIC 166260
7 ny20006478x10_graphic03.jpg GRAPHIC 35752
8 ny20006478x10_graphic04.jpg GRAPHIC 329745
9 ny20006478x10_graphic05.jpg GRAPHIC 203401
10 ny20006478x10_graphic06.jpg GRAPHIC 313708
11 ny20006478x10_graphic07.jpg GRAPHIC 91420
12 ny20006478x10_graphic08a.jpg GRAPHIC 32598
13 ny20006478x10_graphic08b.jpg GRAPHIC 139731
14 ny20006478x10_graphic08c.jpg GRAPHIC 166445
15 ny20006478x10_graphic09.jpg GRAPHIC 6973
16 ny20006478x10_pc01.jpg GRAPHIC 832057
17 ny20006478x10_pc02.jpg GRAPHIC 759156
  Complete submission text file 0001140361-23-035323.txt   16093841
Mailing Address 611 GATEWAY BLVD., SUITE 710 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 710 SOUTH SAN FRANCISCO CA 94080 650-871-0761
CATALYST BIOSCIENCES, INC. (Filer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 000-51173 | Film No.: 231098246
SIC: 2834 Pharmaceutical Preparations